New pill offers hope in fight against pancreatic cancer
Friday, November 20, 2026
The treatment, known as daraxonrasib, was tested in 61 patients whose pancreatic cancer had spread to other parts of the body.

A daily pill used alongside chemotherapy has shown promising results in patients with advanced pancreatic cancer, with tumours becoming undetectable on scans in some patients during an early clinical trial, according to a story published by BBC News on Friday, November 20.

The treatment, known as daraxonrasib, was tested in 61 patients whose pancreatic cancer had spread to other parts of the body.

Results showed that tumours stopped growing in 90 percent of the patients, while just over 60 percent experienced a reduction in tumour size or complete disappearance of the tumours.

In approximately eight percent of participants, equivalent to one in 12, the cancer could no longer be detected through CT scans.

The findings have raised hopes of progress against pancreatic cancer, which is among the hardest cancers to treat and has the lowest survival rate of all common cancers in the UK.

Cancer Research UK described the findings as the biggest leap forward in decades for patients with the disease.

Dr Sam Godfrey, from the charity said that the drug had found a way of targeting cancer mutations previously considered difficult to treat.

"We are finally seeing progress in pancreatic cancer which is so long overdue,” he said.

Experts say that pancreatic cancer is particularly difficult to treat because tumours often continue growing after initially responding to chemotherapy. Patients with advanced disease typically survive months rather than years.

The trial followed participants for an average of 18 months. Some had not experienced a return of their cancer during that period.

However, doctors cautioned that the results do not establish that the treatment can cure pancreatic cancer. Further studies and longer follow-up are needed to establish how long the drug can control the disease and whether the responses translate into longer survival.

Dr Wungki Park, from Memorial Sloan Kettering Cancer Center in the United States, who is involved in the trial, said the results were encouraging, with patients experiencing deeper tumour responses and longer periods of disease control.

He said the improvements could eventually translate into longer survival.

Daraxonrasib belongs to a group of medicines known as KRAS inhibitors. It works by targeting specific RAS mutations that contribute to the growth of cancer cells and are found in most pancreatic cancers.

Researchers are interested in its potential application in other cancers, including lung and ovarian cancer, which can carry similar mutations.

Early progress in pancreatic cancer could offer opportunities for research into treatments for other cancers.

Professor Elena Garralda, chair of the European Organisation for Research and Treatment of Cancer conference where the findings are being presented, said the results suggested that combining the drug with chemotherapy could improve overall survival and delay the return of tumour growth.

Further research will be necessary to establish the treatment’s long-term benefits, including whether patients can achieve lasting remission.

According to the latest available estimates from the World Health Organization’s International Agency for Research on Cancer (IARC), pancreatic cancer accounted for 531,318 new cases and 490,786 deaths worldwide in 2024, ranking it as the sixth leading cause of cancer deaths globally.